Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients

Clinical Infectious Diseases

Volumn 26, Issue 2, 1998, Pages 461-467

  Noskin, Gary A ^a   Pietrelli, Larry ^b   Coffey, Gwen ^b   Gurwith, Marc ^b   Liang, Li Jung ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; BILIRUBIN; CREATININE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CULTURE; CANDIDIASIS; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNGEMIA; HUMAN; IMMUNE DEFICIENCY; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL;

EID: 0031905777     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/516314     Document Type: Article

References (18)

1. Antrum J. Meeting the challenge of systemic fungal infections in cancer: nursing implications. Eur J Haematol Suppl 1996;57:7-11.
2. Taylor GD, Buchanan-Chell M, Kirkland T, McKenzie M, Wiens R. Trends and sources of nosocomial fungaemia. Mycoses 1994; 37: 187-90.
3. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-30.
4. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6:428-42.
5. Terrell CL, Hughes CE. Antifungal agents used for deep-seated mycotic infections. Mayo Clin Proc 1992;67:69-91.
6. Allende MC, Lee JW, Francis P, et al. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother 1994; 38:518-22.
7. Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik J-A. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 1996;173:1208-15.
8. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995;21:1145-53.
9. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Tonilopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989;11:379-90.
10. Pittet D, Wenzel RP. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med 1995;155:1177-84.
11. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. JAMA 1994;271:1598-601.
12. Nguyen MH, Peacock JE, Morris AJ. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996;100:617-23.
13. Debusk CH, Daoud R, Thirumoorthi MC, Wilson FM, Khatib R. Candidemia: current epidemiologic characteristics and a long-term follow-up of the survivors. Scand J Infect Dis 1994;26:697-703.
14. Meunier-Carpentier F, Kiehn TE, Armstrong D. Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality. Am J Med 1981;71:363-70.
15. Horn R, Wong B, Kiehn TE, Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1985;7:646-55.
16. Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data. Arch Intern Med 1995;155:1093-8.
17. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996;22(suppl 2):S133-44.
18. Sarosi GA. Amphotericin B: still the 'gold standard' for antifungal therapy. Postgrad Med 1990; 88:151-66.